APA (7th ed.) Citation

RE, P., MA, N., T, B., E, M., S, F., AJ, G., . . . Davies, M. (2012). Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: A randomized, open-label trial. Diabetes Care, 35(10), 1986.

Chicago Style (17th ed.) Citation

RE, Pratley, et al. "Efficacy and Safety of Switching from the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-treated Patients with Type 2 Diabetes: A Randomized, Open-label Trial." Diabetes Care 35, no. 10 (2012): 1986.

MLA (9th ed.) Citation

RE, Pratley, et al. "Efficacy and Safety of Switching from the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-treated Patients with Type 2 Diabetes: A Randomized, Open-label Trial." Diabetes Care, vol. 35, no. 10, 2012, p. 1986.